Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Shares gained about 20% over 21 trading days and closed at a new high. A raised 2026 outlook and S&P 500 inclusion effective September 21 support momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Strong Cash Flow ā¢ Margin Compression ā¢ Elevated Leverage ILMN remains profitable with solid cash generation and manageable debt, but weakening margins/liquidity and sharply elevated valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ā¢ Strong monthly rally ā¢ $245 resistance ā¢ Volatile pullback Support Level: $228ā$229 Resistance Level: $245 ILMN gained about 12% over the last month, but with resistance near $245 and elevated volatility, watch $228ā$229 support before chasing the rally.
Sentiment & News
Key News Insights: ā¢ Raised Guidance ā¢ S&P Inclusion ā¢ Margin Risks Illumina's earnings beat, raised outlook, S&P 500 inclusion, and oncology growth strengthen momentum, though valuation and margin risks warrant caution.
AI Summary
Illumina's thesis has shifted to proving NovaSeq X placements can drive durable consumables-led growth and renewed operating leverage, but with shares already pricing in much of the recovery, investors should wait for sustained margin and free-cash-flow improvement before adding aggressively.
Description
Illumina, Inc. supplies sequencing and array-based instruments, consumables and related services for genetic and genomic analysis used across research and clinical environments, including applications in oncology, reproductive health and agriculture. Its clientele includes academic and government research centers, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories and consumer genomics firms, and it sells directly in major regions and through life-science distributors worldwide; the company was founded in 1998 and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 28 | Oct 5 | ILMN | Illumina, Inc. | Shares gained about 20% over 21 trading days and closed at a new high. A raised 2026 outlook and S&P 500 inclusion effective September 21 support momentum. | Closed | +8.0% |
| Sep 16 | Sep 23 | ILMN | Illumina, Inc. | Shares gained 21.6% over 21 trading days and broke above the prior $227.69 peak. Earnings and revenue exceeded expectations, guidance improved, and S&P 500 inclusion effective September 21 may create near-term index demand. | Closed | +11.6% |